Workflow
AS Ekspress Grupp: Consolidated unaudited interim report for Q4 and 12 months of 2025
Globenewswire· 2026-02-20 06:00
Core Insights - Ekspress Grupp's revenue continued to grow in Q4 and for the full year 2025, driven by investments in conference business, ticket sales, and digital outdoor screens, alongside strong growth in digital subscriptions [1][9] Revenue Performance - Q4 2025 revenue increased by EUR 0.4 million (+2%) year-over-year, totaling EUR 23.9 million, while the full year revenue rose by EUR 4.1 million (+5%) to EUR 80.2 million [1][8] - The main contributors to revenue growth included the Estonian Training and Conference Centre and UAB Kenton Baltic, along with Delfi Lithuania's AI project and growth in digital subscriptions and ticket sales [1][9] Digital Revenue Growth - Digital revenue for the full year increased by 5%, with nearly 18,000 new digital subscriptions (+7%), reaching a total of 256,000 subscriptions by the end of Q4 2025 [2][11] - Digital revenue accounted for 86% of total revenue at the end of Q4 2025, up from 85% the previous year [11][22] Ticket Sales and Outdoor Screens - Revenue from ticket sales platforms increased by 6% in Q4, while outdoor screen revenue grew by 16%, supported by an expanded network of screens [3][22] Profitability Metrics - Q4 2025 EBITDA totaled EUR 5.3 million, a 1% increase year-over-year, with a margin of 22% [4][13] - Full year EBITDA also increased by 1% to EUR 10.8 million, with a margin of 13% [4][13] Net Profit and Loss - The consolidated net loss for Q4 2025 was EUR 0.9 million, a decrease of EUR 4.0 million from the previous year, while the full year net profit totaled EUR 1.0 million, down by EUR 2.2 million [5][16] - Excluding one-off expenses, the net profit for Q4 was EUR 3.3 million (+6%), and for the full year, it was EUR 3.2 million, approximately the same as last year [5][15][16] Cash Position and Liquidity - As of December 31, 2025, the Group had available cash of EUR 14.0 million, up from EUR 9.0 million the previous year, indicating strong liquidity [7][17] - The Group's net debt decreased to EUR 13.1 million from EUR 19.6 million in the previous year [17] Acquisitions and Strategic Growth - In December 2025, the Group acquired Liikluslab Baltic OÜ, aiming to expand its digital business and enter a new market segment [6]
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Globenewswire· 2026-02-20 06:00
Core Insights - Roche's New Drug Application for giredestrant has been accepted by the U.S. FDA for treating advanced ER-positive breast cancer, with a decision expected by December 18, 2026 [1][7] - Giredestrant in combination with everolimus has shown significant efficacy in delaying disease progression, with a 44% reduction in risk in the intention-to-treat population and 62% in the ESR1-mutated population [2][7] Company Developments - The acceptance of the filing is based on positive results from the phase III evERA Breast Cancer study, which demonstrated improved progression-free survival (PFS) compared to standard therapies [2][9] - Roche plans to submit additional data from the giredestrant clinical program to other global health authorities, indicating a broad strategy for regulatory approval [4][6] Clinical Study Results - In the ESR1-mutated population, median PFS was 9.99 months for giredestrant plus everolimus versus 5.45 months for the comparator, while in the ITT population, it was 8.77 months versus 5.49 months [2][10] - Overall survival data showed a positive trend, with HR of 0.69 in the ITT population and 0.62 in the ESR1-mutated population, although data were still immature at the time of analysis [3][10] Market Context - ER-positive breast cancer represents approximately 70% of breast cancer cases, and there is a significant need for effective treatments due to resistance to existing endocrine therapies [5][13] - Giredestrant's oral formulation aims to provide a less invasive treatment option, potentially improving patient adherence and quality of life [5][11] Future Outlook - Roche's extensive clinical development program for giredestrant includes multiple phase III trials across various treatment settings, reinforcing its commitment to addressing the needs of patients with ER-positive breast cancer [12][15] - Upcoming data from the lidERA trial and the persevERA readout are expected to further support giredestrant's role in the treatment landscape for ER-positive breast cancer [6][12]
dsm-firmenich publishes 2025 Integrated Annual Report
Globenewswire· 2026-02-20 06:00
Core Insights - dsm-firmenich published its Integrated Annual Report (IAR) for 2025, highlighting its innovation-led growth agenda and strategic advancements [1] - The report provides a comprehensive overview of the company's financial and non-financial progress, focusing on becoming a fully consumer-focused entity in nutrition, health, and beauty [2] Financial Performance - The IAR details the Group's performance and the delivery of synergies aimed at creating sustainable long-term value for stakeholders [2] Business Units and Innovations - Each Business Unit's breakthrough innovations are reviewed, including the recent divestment of the Animal Health & Nutrition business [3] Sustainability Efforts - The report emphasizes the company's positive impact on climate, nutrition, health, and people, with sustainability statements aligned with European Sustainability Reporting Standards [3] Accessibility of the Report - The 2025 IAR is available on a dedicated website, including a downloadable version in ESEF format as per European Commission regulations [4] Company Overview - dsm-firmenich operates in nearly 60 countries, generating revenues exceeding €12 billion, and employs around 30,000 people [5]
Apollo Provides $1 Billion Hybrid Capital Solution to Aldar
Globenewswire· 2026-02-20 06:00
Core Insights - Apollo has invested $1 billion in subordinated hybrid notes issued by Aldar Properties, marking its fifth investment in the company since 2022, with total commitments reaching approximately $2.9 billion [1][2][3] - The investment aims to enhance Aldar's balance sheet flexibility and support its growth agenda, which includes landbank replenishment, portfolio expansion, and strategic acquisitions [2][3] - This transaction is noted as one of the largest foreign direct investments in Abu Dhabi's private sector and the largest corporate hybrid private placement in the region [3] Apollo's Investment Strategy - Apollo's ability to provide flexible capital solutions is highlighted, with a focus on meeting the needs of corporate clients and investors [3][4] - The investment reflects Apollo's commitment to the Abu Dhabi region and its confidence in Aldar's management and growth trajectory [3] Aldar's Business Overview - Aldar is a leading real estate developer and investment manager in Abu Dhabi, with a strategic landbank of 60 million square meters [7][8] - The company operates two core business segments: Aldar Development, which focuses on master development and community creation, and Aldar Investment, which manages a diversified portfolio of over AED 49 billion in income-generating real estate assets [8][9] Future Growth Potential - Aldar's develop-to-hold pipeline is valued at close to $5 billion, indicating significant growth potential through acquisitions and development projects [3][9] - The partnership with Apollo is expected to enhance Aldar's ability to capitalize on attractive opportunities in its core markets [3][9]
SIKA REPORTS FULL-YEAR 2025 RESULTS – EXECUTING PLAN TO ACCELERATE GROWTH
Globenewswire· 2026-02-20 04:00
Core Insights - Sika reported a decline in sales for 2025, with total revenues of CHF 11,201.3 million, down 4.8% year-on-year, but achieved a 0.6% growth in local currencies, indicating market share gains across all regions despite challenging conditions in the construction industry [3][5][19] - The company is implementing its Fast Forward program to enhance efficiency and innovation, expecting to generate annual savings of CHF 150 to 200 million by 2028, with a significant portion of these savings anticipated to take effect in 2026 [4][11][10] - Sika's EBITDA margin for 2025 was reported at 18.4%, with an adjusted margin of 19.2% after accounting for one-off costs related to the Fast Forward program, demonstrating strong core business profitability [4][5][17] Financial Performance - Sika's net profit for 2025 was CHF 1,045 million, a decrease of 16.2% from CHF 1,248 million in 2024, with diluted earnings per share falling to CHF 6.50 from CHF 7.76 [5][6][17] - Operating free cash flow was CHF 1,356 million, slightly down from CHF 1,403 million in 2024, but cash conversion improved to 12.1% of sales from 11.9% [5][6][17] - The company proposed an increase in the dividend to CHF 3.70 per share, reflecting a 2.8% year-on-year increase [5][13] Market Dynamics - In the EMEA region, Sika achieved a sales growth of 2.2% in local currencies, with particularly strong performance in the Middle East and Africa [7] - The Americas region also saw a 2.2% increase in sales in local currencies, although the second half of the year faced challenges due to a government shutdown affecting commercial construction [8] - The Asia/Pacific region experienced a decline of 5.3% in local currencies, primarily due to a significant drop in the Chinese construction business, although excluding this segment, the region recorded positive organic growth of 2.5% [9] Strategic Initiatives - The Fast Forward program aims to streamline operations and enhance digital transformation, with targeted structural adjustments in China and efficiency measures in other markets [10][11] - Sika is focused on sustainable performance, achieving a 6.1% reduction in Scope 1 and 2 GHG emissions and improvements in water discharge and waste management [12] - The company remains committed to its medium-term strategic targets for sustainable and profitable growth, with expectations of sales growth of 1% to 4% in local currencies for 2026 [15][16]
EIS Approval for Patterson Lake South Project
Globenewswire· 2026-02-20 01:48
Core Viewpoint - Paladin Energy Ltd has received Ministerial approval for its Environmental Impact Statement (EIS) for the Patterson Lake South (PLS) Project, marking a significant regulatory milestone for the project [1][2]. Regulatory Approval - The Saskatchewan Minister of Environment has formally approved the EIS for the PLS Project, which is characterized as shallow and high grade [2]. - This approval follows the technical acceptance of the EIS in June 2025 and an extensive public review period from July to September 2025 [2]. Project Development - The Environmental Assessment approval is a prerequisite for obtaining necessary permits and licenses from provincial and federal authorities, which are essential for the construction and operation of the PLS Project [2]. - Paladin is actively collaborating with the Canadian Nuclear Safety Commission (CNSC) to advance the licensing process for the PLS Project at the federal level [3]. Government Support - Saskatchewan Premier Scott Moe expressed support for Paladin's sustainable development approach for the PLS Project, highlighting its importance to the province's energy sector [4]. - Minister of Environment Darlene Rowden emphasized the project's alignment with Saskatchewan's Growth Plan and its role as an energy supplier, noting the robust Environmental Assessment process it underwent [4]. Company Leadership - Paladin's Managing Director and CEO, Paul Hemburrow, stated that the approval reflects the company's commitment to sustainable and safe development, which is economically and strategically significant for Canada [4].
Blue Hat Interactive Entertainment Technology Announces Pricing of US$6.4 Million Public Offering
Globenewswire· 2026-02-20 01:15
Core Viewpoint - Blue Hat Interactive Entertainment Technology has announced a public offering of 32,000,000 Units at a price of US$0.20 per Unit, aiming to raise approximately US$6.4 million before expenses [1][3]. Offering Details - Each Unit consists of one ordinary share and one warrant, with the warrant initially exercisable for one ordinary share at an exercise price of US$0.20 [1][2]. - The warrants will expire one year from issuance and can be exercised immediately, with adjustments to the exercise price occurring on the 2nd and 5th trading days post-offering [2]. - The offering is expected to close on February 23, 2026, subject to customary closing conditions [3]. Underwriter Information - Maxim Group LLC is acting as the sole underwriter for the offering [5]. - The underwriter has a 15-day option to purchase up to 4,800,000 additional Units, which may include ordinary shares and/or warrants [4]. Company Background - Blue Hat was previously involved in communication services and is now expanding into commodity trading, aiming to become a leading intelligent commodity trader globally [8].
UPDATE – AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results
Globenewswire· 2026-02-20 01:13
Core Insights - AMN Healthcare Services, Inc. reported a fourth quarter revenue of $748 million, marking a 2% increase year-over-year, while the full year revenue decreased by 8% to $2.730 billion [3][15] - The company experienced a net loss of $7.7 million in Q4 2025, with an adjusted diluted EPS of $0.22, down 70% from the previous year [7][15] - The company is strategically positioned to capture market share in nurse and allied staffing, focusing on innovative workforce solutions amid industry challenges [5][6] Financial Performance - Q4 2025 revenue was $748.2 million, a 2% increase from Q4 2024, while full year revenue was $2,730.4 million, an 8% decrease from 2024 [3][15] - Gross profit for Q4 2025 was $195.1 million, down 11% year-over-year, with a gross margin of 26.1%, a decline of 370 basis points [3][12] - The company reported a net loss of $7.7 million for Q4 2025, compared to a net loss of $188 million in the same quarter last year [7][15] Segment Performance - The Nurse and Allied Solutions segment generated $491 million in revenue for Q4 2025, an 8% increase year-over-year, while the Physician and Leadership Solutions segment reported $170 million, down 2% year-over-year [9][10] - The Technology and Workforce Solutions segment saw a revenue decline of 18% year-over-year, totaling $88 million [11] - Labor disruption revenue contributed $124 million in Q4 2025, highlighting the impact of large labor disruption events [9] Operational Highlights - Cash flow from operations was $76 million for Q4 2025, with a total of $269 million for the full year [8][19] - The company reduced its debt by $75 million in Q4 2025, totaling a $285 million reduction for the year [8][19] - AMN Healthcare's strategic investments in technology and automation have improved fulfillment scalability and order fill rates [6] Future Outlook - For Q1 2026, consolidated revenue is projected to be between $1.225 billion and $1.240 billion, representing a year-over-year increase of 78-80% [21] - The Nurse and Allied Solutions segment is expected to see revenue growth of 137-139% compared to the prior year, driven by anticipated labor disruption revenue of approximately $600 million [21] - The company anticipates a gross margin of 23.5% to 24.0% for Q1 2026, reflecting ongoing efforts to improve operational efficiency [21]
Bimergen Energy Corporation Announces Pricing of Public Offering and NYSE American Listing
Globenewswire· 2026-02-20 01:05
Newport Beach, CA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bimergen Energy Corporation (“Bimergen” or the “Company”) (NYSE American: BESS, BESSWS), a utility-scale battery energy storage systems (BESS) asset owner, project developer, and independent power provider, today announced the pricing of an underwritten public offering of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and one accompanying warrant per common stock or Pre-Funded Warrant, at a public offering price of $4.00, fo ...
Transocean Ltd. Reports Fourth Quarter and Full Year 2025 Results
Globenewswire· 2026-02-20 00:23
Core Viewpoint - Transocean Ltd. reported its financial results for the fourth quarter and full year of 2025, highlighting significant improvements in operational efficiency and financial restructuring, despite a substantial net loss attributable to controlling interest. Financial Performance Summary - Contract drilling revenues for 2025 reached $3.965 billion, a 13% increase from $3.524 billion in 2024 [7] - Adjusted EBITDA was $1.37 billion, up 19% from $1.148 billion in 2024, with an adjusted EBITDA margin of 34.6% [5][7] - Net loss attributable to controlling interest was $2.915 billion, translating to a basic and diluted loss per share of $3.04 [7][21] - Cash flows from operations were $749 million, an increase of 68% compared to the previous year [7] - Free cash flow improved to $626 million, up from $193 million in 2024 [7] Operational Highlights - The company achieved a revenue efficiency of 96.5%, up from 94.5% in 2024 [7] - The total principal amount of debt was reduced to $5.686 billion, down $1.258 billion or 18% [7] - The company added $839 million in contract backlog at a weighted average dayrate of $453,000 [7] Fourth Quarter Performance - In Q4 2025, contract drilling revenues were $1.043 billion, a 1.5% increase from the prior quarter [11] - Net income attributable to controlling interest for Q4 was $25 million, compared to a loss of $1.923 billion in Q3 [11] - Adjusted EBITDA for Q4 was $385 million, slightly down from $397 million in Q3 [11] Future Outlook - For Q1 2026, contract drilling revenues are expected to be between $1.020 billion and $1.050 billion, with full-year guidance set at $3.800 billion to $3.950 billion [10] - The company aims to maintain a revenue efficiency of 96.5% for the full year of 2026 [10] Strategic Initiatives - The company announced a definitive agreement to combine with Valaris, which is expected to enhance fleet capabilities and financial flexibility [5] - The primary objective for 2026 is to exceed customer expectations by delivering safe and efficient operations [4]